CD90表达在癌症患者中的预后及临床病理价值：一项系统评价与荟萃分析
Prognostic and clinicopathological value of CD90 expression in cancer patients: a systematic review and meta-analysis.
作者信息
Koh Hyun Min, Lee Hyun Ju, Kim Dong Chul
机构信息
Department of Pathology, Gyeongsang National University Changwon Hospital, Changwon, Korea.
Department of Pathology, Soonchunhyang University College of Medicine, Cheonan, Korea.
出版信息
Transl Cancer Res. 2021 Jul;10(7):3356-3363. doi: 10.21037/tcr-21-266.
BACKGROUND
Recent studies have shown that CD90 has an important role in cancer development. Moreover, CD90 is reportedly associated with cancer progression, metastasis, and poor prognosis. Thus, we performed this meta-analysis to investigate the prognostic and clinicopathological value of CD90 expression in patients with cancer.
METHODS
Eligible studies were collected by searching PubMed, Embase, and the Cochrane library. The pooled results were analyzed to reveal the association between CD90 expression and survival as well as the clinicopathological characteristics of cancer patients.
RESULTS
CD90 overexpression was associated with poor survival in cancer patients [for overall survival, hazard ratio (HR): 2.56, 95% confidence interval (CI): 1.42-4.62, P=0.002; for disease-free survival, HR: 1.88, 95% CI: 1.08-3.27, P=0.025] and was also significantly correlated with a larger tumor size [odds ratio (OR): 1.97, 95% CI: 1.01-3.85, P=0.048), higher tumor grade (OR: 2.72, 95% CI: 1.33-5.54, P=0.006), lymph node metastasis (OR: 3.66, 95% CI: 1.14-11.78, P=0.029), and higher tumor-node-metastasis stage (OR: 4.79, 95% CI: 2.28-10.04, P<0.001).
CONCLUSIONS
CD90 overexpression could predict poor prognosis and may hence be a potential prognostic biomarker for cancer patients.
背景
近期研究表明，CD90在癌症发展过程中发挥着重要作用。此外，据报道CD90与癌症进展、转移及不良预后相关。因此，我们开展了这项荟萃分析，以探究CD90表达在癌症患者中的预后及临床病理价值。
方法
通过检索PubMed、Embase和Cochrane图书馆收集符合条件的研究。对汇总结果进行分析，以揭示CD90表达与生存率之间的关联以及癌症患者的临床病理特征。
结果
CD90过表达与癌症患者的不良生存相关[总生存期，风险比（HR）：2.56，95%置信区间（CI）：1.42 - 4.62，P = 0.002；无病生存期，HR：1.88，95% CI：1.08 - 3.27，P = 0.025]，并且还与更大的肿瘤大小[比值比（OR）：1.97，95% CI：1.01 - 3.85，P = 0.048]、更高的肿瘤分级（OR：2.72，95% CI：1.33 - 5.54，P = 0.006）、淋巴结转移（OR：3.66，95% CI：1.14 - 11.78，P = 0.029）以及更高的肿瘤-淋巴结-转移分期（OR：4.79，95% CI：2.28 - 10.04，P < 0.001）显著相关。
结论
CD90过表达可预测不良预后，因此可能是癌症患者潜在的预后生物标志物。
Zotero 插件